Concepedia

Michael Eschenberg

ME

14

Publications

2.2K

Citations

13

H-Index

2003

Active since

Affiliations

Amgen (United States)(Current)

Cornell University

Center for Molecular Medicine and Immunology

Michael Eschenberg is an author at Amgen (United States) specializing in medicine, pharmacology, and health sciences.

Top concepts

Publications per year

2003–2015

14

Publications

14

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Steven I. Sherman, Lori J. Wirth, Jean-Pierre Droz et al. · New England Journal of Medicine · 2008 · 471 citations · Full text

FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality

Victoria Shalhoub, Edward Shatzen, Sabrina C. Ward et al. · Journal of Clinical Investigation · 2012 · 401 citations · Full text

, , +21

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

Martin Schlumberger, Rossella Elisei, Lars Bastholt et al. · Journal of Clinical Oncology · 2009 · 340 citations

Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development

Ryan E. Morgan, Michael Trauner, Carlo J. van Staden et al. · Toxicological Sciences · 2010 · 327 citations · Full text

, , +21

Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma

John P. Leonard, Morton Coleman, Jamie Ketas et al. · Journal of Clinical Oncology · 2003 · 252 citations

Rows per page

1–5 of 14